Harmony M
Primær information
- Handelsnavn:
- Harmony M Pulver
- Aktiv bestanddel:
- thifensulfuron-methyl, thifensulfuron, metsulfuron-methyl, metsulfuron
- Tilgængelig fra:
- Du Pont Danmark ApS
- INN (International Name):
- thifensulfuron-methyl, thifensulfuron, metsulfuron-methyl, metsulfuron
- Lægemiddelform:
- Pulver
- Sammensætning:
- 682 g/kg thifensulfuron-methyl; (~ 657 g/kg thifensulfuron; 68 g/kg metsulfuron-methyl; (~ 65,5 g/kg metsulfuron
- Brugt til:
- Planter
- Medicin typen:
- agrokemiske
Dokumenter
- for den brede offentlighed:
- Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.
Anmode informationsbrochure for offentligheden.
- for sundhedspersonale:
- Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.
Anmode informationsbrochure for sundhedspersonale.
Lokation
- Fås i:
-
Danmark
- Sprog:
- dansk
Andre oplysninger
Status
- Kilde:
- SEGES Landbrug & Fødevarer
- Autorisation status:
- Udgået
- Autorisationsnummer:
- 3-133
- Sidste ændring:
- 07-02-2018
- Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.
Anmode informationsbrochure for offentligheden.
- Adgang til dette dokument er kun tilgængelig for registrerede brugere.
Tilmeld dig nu for fuld adgang
11-4-2018
![Orphan designation: 1-[[[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride, for the: Treatment of soft tissue sarcoma](/web/assets/global/img/flags/eu.png)
Orphan designation: 1-[[[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride, for the: Treatment of soft tissue sarcoma
Europe - EMA - European Medicines Agency
26-3-2018
![Orphan designation: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid, for the: Treatment of cystic fibrosis](/web/assets/global/img/flags/eu.png)
Orphan designation: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid, for the: Treatment of cystic fibrosis
Europe - EMA - European Medicines Agency
21-3-2018

Orphan designation: (E)-(6-((N-methyl-((3-methylbenzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl phosphate, bis ethanolamine salt (afabicin), for the: Treatment of osteomyelitis
Europe - EMA - European Medicines Agency
19-10-2017

Orphan designation: (1-Methyl-2-nitro-1H-imidazole-5-yl)methyl N,N’-bis(2-bromoethyl)diamidophosphate, for the: Treatment of pancreatic cancer
Europe - EMA - European Medicines Agency
28-9-2017
![Opinion/decision on a Paediatric investigation plan (PIP): -, 5, 7-dihydroxy-2-[3-hydroxy-4-methoxy-2-(2-methyl-2-propenyl) phenyl]-6, 8-bis (2-methyl-2-propenyl)-4H-chromen-4-one, Therapeutic area: Cardiovascular diseases](/web/assets/global/img/flags/eu.png)
Opinion/decision on a Paediatric investigation plan (PIP): -, 5, 7-dihydroxy-2-[3-hydroxy-4-methoxy-2-(2-methyl-2-propenyl) phenyl]-6, 8-bis (2-methyl-2-propenyl)-4H-chromen-4-one, Therapeutic area: Cardiovascular diseases
Europe - EFSA - European Food Safety Authority EFSA Journal
5-9-2017
![Orphan designation: Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate, for the: Treatment of pulmonary arterial hypertension](/web/assets/global/img/flags/eu.png)
Orphan designation: Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate, for the: Treatment of pulmonary arterial hypertension
Europe - EMA - European Medicines Agency
21-3-2018

EU/3/14/1363 (Quintiles Ireland Limited)
EU/3/14/1363 (Active substance: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid) - Transfer of orphan designation - Commission Decision (2018)1818 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/131/14/T/01
Europe -DG Health and Food Safety
26-2-2018

EU/3/18/1972 (CATS Consultants GmbH)
EU/3/18/1972 (Active substance: 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride) - Orphan designation - Commission Decision (2018)1256 of Mon, 26 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/202/17
Europe -DG Health and Food Safety
30-8-2017

EU/3/07/518 (Bayer AG)
EU/3/07/518 (Active substance: Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate) - Transfer of orphan designation - Commission Decision (2017)5980 of Wed, 30 Aug 2017 European Medicines Agency (EMA) procedure number: EMEA/OD/088/07/T/02
Europe -DG Health and Food Safety